Business Wire

DealCloud Appoints James Brierley as Solutions Engineer for EMEA

Share

DealCloud, the premier provider of deal, relationship, and firm management software to capital market firms, announces the appointment of James Brierley as Solutions Engineer, based in London. With more than 7 years of experience across asset classes with a technology focus, Brierley’s appointment will help fuel the DealCloud Solutions Engineering program in the EMEA region.

Prior to joining DealCloud, Brierley led technology efforts at Park Square Capital, a leading private debt manager. He worked across the organization with a remit of procuring best-in-class technology solutions to support the next stage of Park Square’s growth.

Brierley’s first-hand knowledge of the available technology in the private capital markets will ensure DealCloud clients — both current and prospective — are well-placed to maximize the value that a solution like DealCloud can provide.

“Having witnessed the shortcomings of generic CRM firsthand, I was fortunate enough to be introduced to DealCloud,” he commented. “Frustratingly, one of the bigger hurdles facing my previous firm — like many in the industry — hinged on being tied into a contract with the aforementioned CRM. After researching the alternatives, DealCloud seemed to solve so many issues facing the firm that I was able to put together a strong business case for migration.”

As a former DealCloud client, Brierley enjoys a unique perspective. “Having gone through the DealCloud sales process, implementation, and account management, I’m well-placed to help our clients connect the dots of their ecosystems and keep up with the ever-growing demands facing firms in the private capital markets,” he remarked.

“We had the pleasure of working with James as a client for several years before he joined us to lead our Solutions Engineering efforts in EMEA,” said Michael Santos, Vice President of EMEA sales for DealCloud. “The volume of large and complex transactions in our industry is on the rise, and DealCloud has taken on a life of its own, expanding outside of just CRM and deal management. James’s industry and product knowledge will ensure our clients are poised to tap into the full potential of the DealCloud solution. His ability to solve problems, break down issues, and rebuild better than before is exactly what we were looking for in this role.”

Brierley began his career at Islandbridge Capital and later joined the operations team at Impax Asset Management. He holds a bachelor’s degree with honors in accounting and finance from Durham University. Outside the office, Brierley is a keen sportsman who particularly enjoys rugby and squash, and describes himself as a born-again cricketer.

About DealCloud

DealCloud, an Intapp company, provides a single-source deal, relationship, and firm management platform to enable more than 900 clients to power their deal-making processes from strategy to origination to execution. We offer fully configurable solutions purpose-built for the complex relationships and structures of private equity and growth capital firms, investment banks, private and publicly traded companies, debt capital providers, and other investors. For more information, visit dealcloud.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Alex Nye
anye@stantonprm.com
646-502-3598

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA ® (ustekinumab) in Europe6.11.2025 09:00:00 EET | Press release

Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr

SES Delivers Solid 9 Months and Q3 2025 Results6.11.2025 08:30:00 EET | Press release

SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted EBITDA(2) of €849 million (+11.0% yoy(1)) Networks (+36.3% yoy(1)) supported by growth in Aviation and Government; Media (+0.7% yoy(1)) with important new long-term renewals signed Solid progress with company integration and synergy execution since Day 1 of transaction closure €1.4 billion of new business and contract renewals signed YTD 2025 – with a total combined gross backlog of €7.1 billion O3b mPOWER satellites 9 &10 successfully launched on 22 July, expected to be in service beginning 2026 – boosting O3b mPOWER network capacity and resilience Collected c.$87 million regarding insurance claim for O3b mPOWER satellites 1-4 w

Transition Industries and Mitsubishi Gas Chemical Sign Agreement for the Purchase and Sale of Ultra-Low Carbon Methanol6.11.2025 06:00:00 EET | Press release

Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, signed a long-term methanol sales and purchase agreement with Mitsubishi Gas Chemical Company, Inc. (MGC) for the offtake of ultra-low carbon methanol. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105695992/en/ Masahiko Naito, Division Director of Mitsubishi Gas Chemical and Rommel Gallo, CEO of Transition Industries sign agreement in Tokyo, November 6, 2025 Under the Agreement, which will become effective upon the Project’s Final Investment Decision (FID), Transition Industries will supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,130 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2029. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corpora

Kinaxis Announces Normal Course Issuer Bid6.11.2025 00:00:00 EET | Press release

Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p

Hyper ® Wins Dual CES 2026 Innovation Awards ® for its Breakthrough Tech Accessories5.11.2025 23:50:00 EET | Press release

Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defining ‘world’s firsts’ in power, connectivity, mobility, and desktop solutions,” said Gabi Iorio, Director of Global Marketing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye